AVROBIO, a leader in lentiviral-based gene therapies, is a clinical-stage company developing disruptive therapies that have the potential to transform patients' lives with a single dose. The Company is focused on the development of its gene therapy candidate, AVR-RD-01, in Fabry disease, as well as additional gene therapy programs in other lysosomal storage disorders including Gaucher disease, cystinosis and Pompe disease. AVROBIO's lentiviral platform has broad potential for other rare and non-rare genetic diseases.

Key Contact

Funding Events

Date	Amount	Type	Investors	Valuation
02/01/18	$60,000,000	Series B	Aisling Capital Atlas Venture Brace Pharma Clarus Ventures Cormorant Asset Management Eventide Asset Management Morningside Venture Surveyor Capital SV Health Investors	undisclosed